The "Pharma 4.0 - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for Pharma 4 was valued at US$13.7 Billion in 2024 and is projected to ...
The report delivers a comprehensive analysis of global biologics sales. Covering cancer antibodies, non-TNF inflammatory mAbs, biosimilars, gene therapy, RNA-based drugs, and more, the report provides ...
The label expansion couls help J&J establish Tremfya as a successor to Stelara, which is now facing a growing biosimilar ...
A doctor can help you understand your options, including alternative drugs such as biosimilars (similar formulations to biologics) and any patient assistance programs available through drug ...
Overall, the study’s findings support the use of Amjevita and Imraldi as equally effective alternatives to Humira in the real ...
“The FDA's filing acceptance of Dr. Reddy's proposed denosumab biosimilar marks an important milestone in bringing this biosimilar medication to more patients throughout the U.S.,” said Milan ...
The inquiry is the latest effort by the European Commission and European countries to scrutinize potential antitrust behavior ...
Steqeyma is indicated for the treatment of plaque psoriasis and psoriatic arthritis in adult and pediatric patients, as well ...
Greater Effectiveness and Enhanced Safety Profiles of Biosimilars Compared to Their Reference Biologics Increasing Their Adoption Worldwid ...
Alvotech acquires Xbrane’s R&D operations and the biosimilar candidate XB003. Xbrane retains some pre-clinical development programs, that it intends to commercialize, and will continue operating as a ...
Samsung Biologics, Hanmi Pharmaceutical Partner to Sell Prolia Biosimilar in Korea Samsung Bioepis and Hanmi Pharmaceutical ...
Celltrion has launched Steqeyma (ustekinumab-stba), its biosimilar of Stelara (ustekinumab), at list price at an 85% discount ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback